Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple breathing exercise shows promise for COPD sufferers

NCT ID NCT07001462

Symptom relief Sponsor: Bugra Kerget Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether a breathing training device (IMT/PEP) could improve lung function and reduce breathlessness in people with severe, exacerbation-prone COPD. 61 stable patients used the device twice daily for 12 weeks alongside their usual medications. Researchers measured changes in breathing strength, lung volume, exercise capacity, and symptom scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inspiratory muscle training and positive expiratory pressure (IMT/PEP) therapy using a dual-function breathing device
What this could lead to
If it works, this could offer a simple, at-home breathing exercise to help COPD patients breathe easier and be more active.
What could go wrong
This is a small, completed trial with only 61 patients, so results may not apply to everyone. The therapy is an add-on to standard care, not a replacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

61 people

The number who actually took part.

Started

Jun 2023

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 40 years and older diagnosed with Group E chronic obstructive pulmonary disease (COPD) according to GOLD 2024 criteria, with moderate to very severe airflow limitation, increased symptom burden, and a history of frequent exacerbations or hospitalizations.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥ 40 years Diagnosis of Group E COPD according to GOLD 2023 criteria Post-bronchodilator FEV₁/FVC \< 0.70 and FEV₁ \< 50% predicted mMRC score ≥ 2 or CAT score ≥ 10 History of ≥2 exacerbations or ≥1 hospitalization in the past year Stable clinical condition (no exacerbation in the past 2 weeks) Ability and willingness to perform IMT/PEP therapy Provided written informed consent Exclusion Criteria: Acute exacerbation of COPD at time of enrollment Contraindications to pulmonary function testing or 6-minute walk test (e.g., recent myocardial infarction, unstable angina) Inability to perform inspiratory or expiratory maneuvers reliably (e.g., due to cognitive or neuromuscular disorders) Significant orofacial muscle weakness unresponsive to modified mouthpiece Participation in another interventional study within the past 3 months Nonadherence to COPD treatment plan Any condition deemed by investigators to interfere with study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD Inspiratory muscle training

Contacts and locations

Locations

  • Ataturk University

    Erzurum, Yakutiye, 25200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.